Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in alzheimer’s disease: The role of the ER-MT cross-talk

Current Alzheimer Research

Volumn 12, Issue 7, 2015, Pages 655-672

  Völgyi, Katalin ^a,b   Juhász, Gábor ^a,b   Kovács, Zsolt ^c   Penke, Botond ^d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c UNIVERSITY OF WEST HUNGARY   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Endoplasmic reticulum; Mitochondria malfunction; Mitochondria associated endoplasmic reticulum membrane; Synaptic mitochondria; Unfolded protein response; amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CALCIUM ION; GLUTATHIONE; MEMBRANE PROTEIN; PYRUVATE DEHYDROGENASE COMPLEX; TAU PROTEIN; VOLTAGE DEPENDENT ANION CHANNEL 1;

ALZHEIMER DISEASE; BRAIN MITOCHONDRION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM MEMBRANE; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; HUMAN; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); UNFOLDED PROTEIN RESPONSE; ANIMAL; METABOLISM; MITOCHONDRION;

ALZHEIMER DISEASE; ANIMALS; ENDOPLASMIC RETICULUM; HUMANS; MITOCHONDRIA;

EID: 84948405715     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150710095035     Document Type: Conference Paper

References (238)

1. [1] Kovacs G. Current concepts of neurodegenerative disease. EMJ Neurology 1: 78-86 (2014).
2. [2] Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, et al. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J Neurochem 117(3): 359-74 (2011).
3. [3] Xie A, Gao J, Xu L, Meng D. Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res Int 2014: 648740 (2014).
4. [4] Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 6(5): 73 (2014).
5. [5] Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14(9): 626-36 (2013).
6. [6] Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther 6(5-8): 72 (2014).
7. [7] Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28(1-2): 67-78 (2004).
8. [8] Unterberger U, Hoftberger R, Gelpi E, Flicker H, Budka H, Voigtlander T. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathol Exp Neurol 65(4): 348-57 (2006).
9. [9] Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7(12): 1013-30 (2008).
10. [10] Soejima N, Ohyagi Y, Nakamura N, Himeno E, Iinuma KM, Sakae N, et al. Intracellular accumulation of toxic turn amyloid-beta is associated with endoplasmic reticulum stress in Alzheimer's disease. Curr Alzheimer Res 10(1): 11-20 (2013).
11. [11] Li JQ, Yu JT, Jiang T, Tan L. Endoplasmic Reticulum Dysfunction in Alzheimer's Disease. Mol Neurobiol 51(1): 383-95 (2014).
12. [12] Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol 12(1): 105-18 (2013).
13. [13] Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 15(4): 233-49 (2014).
14. [14] Placido AI, Pereira CM, Duarte AI, Candeias E, Correia SC, Santos RX, et al. The role of endoplasmic reticulum in amyloid precursor protein processing and trafficking: implications for Alzheimer's disease. Biochim Biophys Acta 1842(9): 1444-53 (2014).
15. [15] Endres K, Reinhardt S. ER-stress in Alzheimer's disease: turning the scale? Am J Neurodegener Dis 2(4): 247-65 (2013).
16. [16] Alberdi E, Wyssenbach A, Alberdi M, Sanchez-Gomez MV, Cavaliere F, Rodriguez JJ, et al. Ca(2+) -dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid beta-treated astrocytes and in a model of Alzheimer's disease. Aging Cell 12(2): 292-302 (2013).
17. [17] Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 8(4): 393-409 (2011).
18. [18] Selfridge JE, E L, Lu J, Swerdlow RH. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis 51: 3-12 (2013).
19. [19] Picone P, Nuzzo D, Caruana L, Scafidi V, Di Carlo M. Mitochondrial dysfunction: different routes to Alzheimer's disease therapy. Oxid Med Cell Longev 2014: 780179 (2014).
20. [20] Bernales S, Soto MM, McCullagh E. Unfolded protein stress in the endoplasmic reticulum and mitochondria: a role in neurodegeneration. Front Aging Neurosci 4: 5 (2012).
21. [21] Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, Madra M, et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 31(21): 4106-23 (2012).
22. [22] Hedskog L, Pinho CM, Filadi R, Ronnback A, Hertwig L, Wiehager B, et al. Modulation of the endoplasmic reticulummitochondria interface in Alzheimer's disease and related models. Proc Natl Acad Sci U SA 110(19): 7916-7921 (2013).
23. [23] Schon EA, Area-Gomez E. Mitochondria-associated ER membranes in Alzheimer disease. Mol Cell Neurosci 55: 26-36 (2013).
24. [24] Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau KF, et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTDassociated TDP-43. Nat Commun 5: 3996 (2014).
25. [25] Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430(7000): 631-9 (2004).
26. [26] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-6 (2002).
27. [27] Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta 1812(12): 1630-9 (2011).
28. [28] Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842(8): 1219-31 (2014).
29. [29] Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 29(12): 609-15 (2008).
30. [30] LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8(7): 499-509 (2007).
31. [31] Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, et al. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci 30(43): 14299-304 (2010).
32. [32] Blair JA, Siedlak SL, Wolfram JA, Nunomura A, Castellani RJ, Ferreira ST, et al. Accumulation of intraneuronal amyloid-beta is common in normal brain. Curr Alzheimer Res 11(4): 317-24 (2014).
33. [33] Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther 5(1): 1 (2013).
34. [34] Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) [Epub ahead of print].
35. [35] Fisher NJ, Rourke BP, Bieliauskas LA, Giordani B, Berent S, Foster NL. Unmasking the heterogeneity of Alzheimer's disease: case studies of individuals from distinct neuropsychological subgroups. J Clin Exp Neuropsychol 19(5): 713-54 (1997).
36. [36] Friedland RP, Koss E, Haxby JV, Grady CL, Luxenberg J, Schapiro MB, et al. NIH conference. Alzheimer disease: clinical and biological heterogeneity. Ann Intern Med 109(4): 298-311 (1988).
37. [37] Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, et al. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tanglepredominant dementia. Acta Neuropathol 124(5): 681-92 (2012).
38. [38] Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of gamma- Secretase dysfunction in familial Alzheimer disease. EMBO J 31(10): 2261-74 (2012).
39. [39] Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16(3): 271-8; discussion 278-84 (1995).
40. [40] Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12): 1791-800 (2002).
41. [41] Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J, et al. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. J Neural Transm 122(7): 1007-18 (2015).
42. [42] Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 129(2): 207-20 (2015).
43. [43] Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123(1): 1-11 (2012).
44. [44] Jellinger KA, Attems J. Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 31(2): 87-98 (2012).
45. [45] Reinhard C, Hebert SS, De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J 24(23): 3996-4006 (2005).
46. [46] Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44): 29615-9 (2008).
47. [47] Leyssen M, Ayaz D, Hebert SS, Reeve S, De Strooper B, Hassan BA. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J 24(16): 2944- 55 (2005).
48. [48] Roch JM, Masliah E, Roch-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, et al. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci USA 91(16): 7450-4 (1994).
49. [49] Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70(1): 1-32 (2003).
50. [50] Lee C, Ferguson M, Chen LB. Construction of the endoplasmic reticulum. J Cell Biol 109(5): 2045-55 (1989).
51. [51] Xu X. Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J Alzheimers Dis 16(2): 211-24 (2009).
52. [52] Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29(41): 13042-52 (2009).
53. [53] Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44(1): 181-93 (2004).
54. [54] Baranello RJ, Bharani KL, Padmaraju V, Chopra N, Lahiri DK, Greig NH, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res 12(1): 32-46 (2015).
55. [55] Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96(7): 3922-7 (1999).
56. [56] Lai A, Sisodia SS, Trowbridge IS. Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J Biol Chem 270(8): 3565-73 (1995).
57. [57] Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, et al. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 274(27): 18851-6 (1999).
58. [58] Choy RW, Cheng Z, Schekman R. Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid beta (Abeta) production in the trans-Golgi network. Proc Natl Acad Sci USA 109(30): E2077-82 (2012).
59. [59] Chyung AS, Greenberg BD, Cook DG, Doms RW, Lee VM. Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 138(3): 671-80 (1997).
60. [60] Shin RW, Saido TC, Maeda M, Kitamoto T. Novel alpha-secretase cleavage of Alzheimer's amyloid beta precursor protein in the endoplasmic reticulum of COS7 cells. Neurosci Lett 376(1): 14-9 (2005).
61. [61] Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta 1801(8): 860-7 (2010).
62. [62] Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, et al. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron 75(5): 824-37 (2012).
63. [63] Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12(4): 487-96 (2013).
64. [64] Lai CS, Preisler J, Baum L, Lee DH, Ng HK, Hugon J, et al. Low molecular weight Abeta induces collapse of endoplasmic reticulum. Mol Cell Neurosci 41(1): 32-43 (2009).
65. [65] Cheng F, Vivacqua G, Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat 42(4): 242-8 (2011).
66. [66] Al-Mansoori KM, Hasan MY, Al-Hayani A, El-Agnaf OM. The role of alpha-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches. Curr Alzheimer Res 10(6): 559-68 (2013).
67. [67] Marsh SE, Blurton-Jones M. Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res Ther 4(2): 11 (2012).
68. [68] Guardia-Laguarta C, Area-Gomez E, Rub C, Liu Y, Magrane J, Becker D, et al. alpha-Synuclein is localized to mitochondriaassociated ER membranes. J Neurosci 34(1): 249-59 (2014).
69. [69] Bravo R, Parra V, Gatica D, Rodriguez AE, Torrealba N, Paredes F, et al. Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int Rev Cell Mol Biol 301: 215-90 (2013).
70. [70] Gidalevitz T, Stevens F, Argon Y. Orchestration of secretory protein folding by ER chaperones. Biochim Biophys Acta 1833(11): 2410-24 (2013).
71. [71] Jansen G, Maattanen P, Denisov AY, Scarffe L, Schade B, Balghi H, et al. An interaction map of endoplasmic reticulum chaperones and foldases. Mol Cell Proteomics 11(9): 710-23 (2012).
72. [72] Maity S, Basak T, Bhat A, Bhasin N, Ghosh A, Chakraborty K, et al. Cross-compartment proteostasis regulation during redox imbalance induced ER stress. Proteomics 14(15): 1724-36 (2014).
73. [73] Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 13(2): 89-102 (2012).
74. [74] Pereira CMF. Crosstalk between endoplasmic reticulum stress and protein misfolding in neurodegenerative diseases. ISRN Cell Biology (2013).
75. [75] Sitia R, Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 426(6968): 891-4 (2003).
76. [76] Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 18(4): 444-52 (2006).
77. [77] Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 7(8): 766-72 (2005).
78. [78] Woehlbier U, Hetz C. Modulating stress responses by the UPRosome: a matter of life and death. Trends Biochem Sci 36(6): 329-37 (2011).
79. [79] Badiola N, Penas C, Minano-Molina A, Barneda-Zahonero B, Fado R, Sanchez-Opazo G, et al. Induction of ER stress in response to oxygen-glucose deprivation of cortical cultures involves the activation of the PERK and IRE-1 pathways and of caspase-12. Cell Death Dis 2: e149 (2011).
80. [80] Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, et al. ERstress- induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 15(5): 481-90 (2013).
81. [81] Urra H, Dufey E, Lisbona F, Rojas-Rivera D, Hetz C. When ER stress reaches a dead end. Biochim Biophys Acta 1833(12): 3507-17 (2013).
82. [82] Ron D. The endoplasmic reticulum unfolded protein response and neurodegeneration. Morimoto RI, and Christen Y, Eds. Protein quality control in neurodegenerative diseases, research and perspectives in Alzheimer’s disease. Berlin Heidelberg: Springer- Verlag (2013).
83. [83] Safra M, Ben-Hamo S, Kenyon C, Henis-Korenblit S. The ire-1 ER stress-response pathway is required for normal secretory-protein metabolism in C. elegans. J Cell Sci 126(Pt 18): 4136-46 (2013).
84. [84] Taylor RC, Dillin A. XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity. Cell 153(7): 1435-47 (2013).
85. [85] Halliday M, Mallucci GR. Targeting the unfolded protein response in neurodegeneration: A new approach to therapy. Neuropharmacology 76 Pt A: 169-74 (2014).
86. [86] Chadwick W, Mitchell N, Martin B, Maudsley S. Therapeutic targeting of the endoplasmic reticulum in Alzheimer's disease. Curr Alzheimer Res 9(1): 110-9 (2012).
87. [87] Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 9(17): 1-34 (2007).
88. [88] Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16(4): 741-61 (2009).
89. [89] Zhu XH, Qiao H, Du F, Xiong Q, Liu X, Zhang X, et al. Quantitative imaging of energy expenditure in human brain. Neuroimage 60(4): 2107-17 (2012).
90. [90] Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 60(5): 748-66 (2008).
91. [91] Takahashi RH, Nam EE, Edgar M, Gouras GK. Alzheimer betaamyloid peptides: normal and abnormal localization. Histol Histopathol 17(1): 239-46 (2002).
92. [92] Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19(14): 2040-1 (2005).
93. [93] Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15(9): 1437-49 (2006).
94. [94] Pagani L, Eckert A. Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis 2011: 925050 (2011).
95. [95] Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161(1): 41-54 (2003).
96. [96] Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26(35): 9057-68 (2006).
97. [97] Park HJ, Kim SS, Seong YM, Kim KH, Goo HG, Yoon EJ, et al. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J Biol Chem 281(45): 34277-87 (2006).
98. [98] Tyler DD, Gonze J, Lamy F, Dumont JE. Influence of mitochondrial inhibitors on the respiration and energy-dependent uptake of iodide by thyroid slices. Biochem J 106(1): 123-33 (1968).
99. [99] Kooistra J, Milojevic J, Melacini G and Ortega J. A new function of human HtrA2 as an amyloid-beta oligomerization inhibitor. J Alzheimers Dis 17(2): 281-94 (2009).
100. [100] Pavlov PF, Wiehager B, Sakai J, Frykman S, Behbahani H, Winblad B, et al. Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J 25(1): 78-88 (2011).
101. [101] Keil U, Hauptmann S, Bonert A, Scherping I, Eckert A, Muller WE. Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations. J Alzheimers Dis 9(2): 139-46 (2006).
102. [102] Olah J, Vincze O, Virok D, Simon D, Bozso Z, Tokesi N, et al. Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alphasynuclein. J Biol Chem 286(39): 34088-100 (2011).
103. [103] Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304(5669): 448-52 (2004).
104. [104] Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase- Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 31(6): 2313-20 (2011).
105. [105] Vangavaragu JR, Valasani KR, Fang D, Williams TD, Yan SS. Determination of small molecule ABAD inhibitors crossing bloodbrain barrier and pharmacokinetics. J Alzheimers Dis 42(1): 333-44 (2014).
106. [106] Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14(10): 1097-105 (2008).
107. [107] Du H, Guo L, Zhang W, Rydzewska M and Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging 32(3): 398-406 (2011).
108. [108] Pinho CM, Teixeira PF, Glaser E. Mitochondrial import and degradation of amyloid-beta peptide. Biochim Biophys Acta 1837(7): 1069-74 (2014).
109. [109] Falkevall A, Alikhani N, Bhushan S, Pavlov PF, Busch K, Johnson KA, et al. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J Biol Chem 281(39): 29096-104 (2006).
110. [110] Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 21(23): 5131-46 (2012).
111. [111] Chou JL, Shenoy DV, Thomas N, Choudhary PK, Laferla FM, Goodman SR, et al. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 74(4): 466-79 (2011).
112. [112] Raichle ME. The brain's dark energy. Sci Am 302(3): 44-9 (2010).
113. [113] Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 105(8-9): 855-70 (1998).
114. [114] Tyler DD. Electron transfer components of the phosphorylating respiratory chain. Arch Int Physiol Biochim 74(2): 321-2 (1966).
115. [115] Parker WD, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40(8): 1302-3 (1990).
116. [116] Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23(3): 371-6 (2002).
117. [117] Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25(1): 105-10 (2004).
118. [118] Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6(6): 323-30 (2006).
119. [119] Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13(12): 1225-40 (2004).
120. [120] Hernandez-Zimbron LF, Luna-Munoz J, Mena R, Vazquez- Ramirez R, Kubli-Garfias C, Cribbs DH, et al. Amyloid-beta peptide binds to cytochrome C oxidase subunit 1. PLoS One 7(8): e42344 (2012).
121. [121] Tyler DD, Butow RA, Gonze J, Estabrook RW. Evidence for the Existence and function of an occult, highly reactive sulphydryl group in the respiratory chain dpnh dehydrogenase. Biochem Biophys Res Commun 19: 551-7 (1965).
122. [122] Gibson GE, Blass JP, Beal MF, Bunik V. The alpha-ketoglutaratedehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol 31(1-3): 43-63 (2005).
123. [123] Stacpoole PW. The pyruvate dehydrogenase complex as a therapeutic target for age-related diseases. Aging Cell 11(3): 371-7 (2012).
124. [124] Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci 924: 170-83 (2000).
125. [125] Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57(5): 695-703 (2005).
126. [126] Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathologyin female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106(34): 14670-5 (2009).
127. [127] Dumont M, Ho DJ, Calingasan NY, Xu H, Gibson G, Beal MF. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med 47(7): 1019-27 (2009).
128. [128] Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 105(1): 91-102 (2012).
129. [129] Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1-2): 91-104 (2010).
130. [130] Moreira PI, Cardoso SM, Santos MS, Oliveira CR. The key role of mitochondria in Alzheimer's disease. J Alzheimers Dis 9(2): 101-10 (2006).
131. [131] Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM, Moreira WL, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 26(1): 59-68 (2011).
132. [132] Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24(2): 565-75 (2004).
133. [133] Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9(2): 147-53 (2006).
134. [134] Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, et al. Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell 3(1): 41-4 (2004).
135. [135] Lopez N, Tormo C, De Blas I, Llinares I, Alom J. Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33(3): 823-9 (2013).
136. [136] Venditti P, Di Stefano L, Di Meo S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion 13(2): 71-82 (2013).
137. [137] Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 281(2): 468-74 (2001).
138. [138] Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Betaamyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80(1): 91-100 (2002).
139. [139] Sergeant N, Wattez A, Galvan-valencia M, Ghestem A, David JP, Lemoine J, et al. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117(2): 293-303 (2003).
140. [140] Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22(1): 76-87 (2006).
141. [141] Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119(6): 873-87 (2004).
142. [142] Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, et al. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 168(5): 1608-18 (2006).
143. [143] Ribas V, Garcia-Ruiz C and Fernandez-Checa JC. Glutathione and mitochondria. Front Pharmacol 5: 151 (2014).
144. [144] Mari M, Morales A, Colell A, Garcia-Ruiz C, Kaplowitz N, Fernandez-Checa JC. Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta 1830(5): 3317-28 (2013).
145. [145] Barbero-Camps E, Fernandez A, Martinez L, Fernandez-Checa JC, Colell A. APP/PS1 mice overexpressing SREBP-2 exhibit combined Abeta accumulation and tau pathology underlying Alzheimer's disease. Hum Mol Genet 22(17): 3460-76 (2013).
146. [146] Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21(12): 4183-7 (2001).
147. [147] Chassaing S, Collin F, Dorlet P, Gout J, Hureau C, Faller P. Copper and heme-mediated Abeta toxicity: redox chemistry, Abeta oxidations and anti-ROS compounds. Curr Top Med Chem 12(22): 2573-95 (2012).
148. [148] Ohyagi Y, Yamada T, Nishioka K, Clarke NJ, Tomlinson AJ, Naylor S, et al. Selective increase in cellular A beta 42 is related to apoptosis but not necrosis. Neuroreport 11(1): 167-71 (2000).
149. [149] Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme upregulation induced by 4-hydroxynonenal is mediated by stressactivated protein kinases pathways. J Neurochem 92(3): 628-36 (2005).
150. [150] Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85(5): 1101-8 (2003).
151. [151] Conte V, Uryu K, Fujimoto S, Yao Y, Rokach J, Longhi L, et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 90(3): 758-64 (2004).
152. [152] Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7): 5892-901 (2005).
153. [153] Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822(5): 639-49 (2012).
154. [154] van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol 5(6) (2013).
155. [155] Knott AB, Perkins G, Schwarzenbacher R and Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9(7): 505-18 (2008).
156. [156] Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromol Med 10(4): 291-315 (2008).
157. [157] Manczak M, Calkins MJ and Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20(13): 2495-509 (2011).
158. [158] Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105(49): 19318-23 (2008).
159. [159] Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21(9): 3017-23 (2001).
160. [160] Trushina E, Nemutlu E, Zhang S, Christensen T, Camp J, Mesa J, et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7(2): e32737 (2012).
161. [161] Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29(28): 9090-103 (2009).
162. [162] Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Dev Biol 22: 79-99 (2006).
163. [163] Yan J, Liu XH, Han MZ, Wang YM, Sun XL, Yu N, et al. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease. Neurobiol Aging 36(1): 211-27 (2015).
164. [164] Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 20 (Suppl 2): S609-31 (2010).
165. [165] Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130(3): 548-62 (2007).
166. [166] Gan X, Wu L, Huang S, Zhong C, Shi H, Li G, et al. Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction. Free Radic Biol Med 75C: 230-240 (2014).
167. [167] Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimers Dis 40(2): 245-56 (2014).
168. [168] Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell 14(2): 193-204 (2008).
169. [169] Qi X, Qvit N, Su YC and Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 126(Pt 3): 789-802 (2013).
170. [170] Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10(6): 839-50 (2006).
171. [171] Jung C, Chylinski TM, Pimenta A, Ortiz D, Shea TB. Neurofilament transport is dependent on actin and myosin. J Neurosci 24(43): 9486-96 (2004).
172. [172] Hollenbeck PJ. The pattern and mechanism of mitochondrial transport in axons. Front Biosci 1: d91-102 (1996).
173. [173] MacAskill AF, Kittler JT. Control of mitochondrial transport and localization in neurons. Trends Cell Biol 20(2): 102-12 (2010).
174. [174] Zinsmaier KE, Babic M, Russo GJ. Mitochondrial transport dynamics in axons and dendrites. Results Probl Cell Differ 48: 107-39 (2009).
175. [175] Pilling AD, Horiuchi D, Lively CM, Saxton WM. Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in Drosophila motor axons. Mol Biol Cell 17(4): 2057-68 (2006).
176. [176] Cai Q, Sheng ZH. Moving or stopping mitochondria: Miro as a traffic cop by sensing calcium. Neuron 61(4): 493-6 (2009).
177. [177] Liu X, Hajnoczky G. Ca2+-dependent regulation of mitochondrial dynamics by the Miro-Milton complex. Int J Biochem Cell Biol 41(10): 1972-6 (2009).
178. [178] Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 20(7): 1438-55 (2011).
179. [179] Sterky FH, Lee S, Wibom R, Olson L, Larsson NG. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc Natl Acad Sci USA 108(31): 12937-42 (2011).
180. [180] De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 16(22): 2720-8 (2007).
181. [181] Nakamura LK, Tyler DD. Induction of D-aldohexoside:cytochrome c oxidoreductase in Agrobacterium tumefaciens. J Bacteriol 129(2): 830-5 (1977).
182. [182] Calkins MJ, Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim Biophys Acta 1812(4): 507-13 (2011).
183. [183] Trimmer PA, Borland MK. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal 7(9-10): 1101-9 (2005).
184. [184] Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J. Alzheimer's presenilin 1 mutations impair kinesinbased axonal transport. J Neurosci 23(11): 4499-508 (2003).
185. [185] Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107(43): 18670-5 (2010).
186. [186] Rui Y, Tiwari P, Xie Z, Zheng JQ. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J Neurosci 26(41): 10480-7 (2006).
187. [187] Tyler DD. Polarographic assay and intracellular distribution of superoxide dismutase in rat liver. Biochem J 147(3): 493-504 (1975).
188. [188] Waagepetersen HS, Hansen GH, Fenger K, Lindsay JG, Gibson G, Schousboe A. Cellular mitochondrial heterogeneity in cultured astrocytes as demonstrated by immunogold labeling of alphaketoglutarate dehydrogenase. Glia 53(2): 225-31 (2006).
189. [189] Vos M, Lauwers E, Verstreken P. Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease. Front Synaptic Neurosci 2: 139 (2010).
190. [190] Brown MR, Sullivan PG, Geddes JW. Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem 281(17): 11658-68 (2006).
191. [191] Billups B, Forsythe ID. Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J Neurosci 22(14): 5840-7 (2002).
192. [192] Tyler DD, Nakamura LK. Conditions for production of 3- ketomaltose from Agrobacterium tumefaciens. Appl Microbiol 21(2): 175-80 (1971).
193. [193] Naga KK, Sullivan PG, Geddes JW. High cyclophilin D content of synaptic mitochondria results in increased vulnerability to permeability transition. J Neurosci 27(28): 7469-75 (2007).
194. [194] Tyler DD, Newton J. Inhibition of succinate oxidation and transport into mitochondria by metal-complexing agents. FEBS Lett 8(6): 325-327 (1970).
195. [195] Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, et al. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20(2): S535-50 (2010).
196. [196] Monteiro-Cardoso VF, Oliveira MM, Melo T, Domingues MR, Moreira PI, Ferreiro E, et al. Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in alzheimer's disease. J Alzheimers Dis 43(4):1375-92 (2015).
197. [197] Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41(1): 17-24 (1997).
198. [198] Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30(36): 11938-50 (2010).
199. [199] Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32(3): 150-9 (2009).
200. [200] Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 4: 13 (2009).
201. [201] Li X, Kumar Y, Zempel H, Mandelkow EM, Biernat J, Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 30(23): 4825-37 (2011).
202. [202] Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science 319(5866): 1086-9 (2008).
203. [203] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6: 39 (2011).
204. [204] Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14): 3650-62 (2007).
205. [205] Stoothoff W, Jones PB, Spires-Jones TL, Joyner D, Chhabra E, Bercury K, et al. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem 111(2): 417-27 (2009).
206. [206] Eckert A, Schulz KL, Rhein V, Gotz J. Convergence of amyloidbeta and tau pathologies on mitochondria in vivo. Mol Neurobiol 41(2-3): 107-14 (2010).
207. [207] Taylor CW, Tovey SC. IP(3) receptors: toward understanding their activation. Cold Spring Harb Perspect Biol 2(12): a004010 (2010).
208. [208] Gunter TE, Sheu SS. Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. Biochim Biophys Acta 1787(11): 1291-308 (2009).
209. [209] Moreau B, Nelson C, Parekh AB. Biphasic regulation of mitochondrial Ca2+ uptake by cytosolic Ca2+ concentration. Curr Biol 16(16): 1672-7 (2006).
210. [210] Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 1777(7-8): 946-52 (2008).
211. [211] Martin LJ. The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis therapy. Biochim Biophys Acta 1802(1): 186-97 (2010).
212. [212] Berridge MJ. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 32(5-6): 235-49 (2002).
213. [213] Grosskreutz J, Van Den Bosch L, Keller BU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 47(2): 165-74 (2010).
214. [214] Ferreira IL, Ferreiro E, Schmidt J, Cardoso JM, Pereira CM, Carvalho AL, et al. Abeta and NMDAR activation cause mitochondrial dysfunction involving ER calcium release. Neurobiol Aging 36(2): 680-92 (2015).
215. [215] Vannuvel K, Renard P, Raes M, Arnould T. Functional and morphological impact of ER stress on mitochondria. J Cell Physiol 228(9): 1802-18 (2013).
216. [216] Schon EA, Area-Gomez E. Is Alzheimer's disease a disorder of mitochondria-associated membranes? J Alzheimers Dis 20(2): S281-92 (2010).
217. [217] Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. J Cell Biol 174(7): 915-21 (2006).
218. [218] Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol 19(2): 81-8 (2009).
219. [219] Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, Cavagna D, et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 175(6): 901-11 (2006).
220. [220] Hayashi T, Su TP. Sigma-1 receptor chaperones at the ERmitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131(3): 596-610 (2007).
221. [221] de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456(7222): 605-10 (2008).
222. [222] Poston CN, Krishnan SC, Bazemore-Walker CR. In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM). J Proteomics 79: 219-30 (2013).
223. [223] Domingues SC, Henriques AG, Wu W, Da Cruz e Silva EF, Da Cruz e Silva OA. Altered subcellular distribution of the Alzheimer's amyloid precursor protein under stress conditions. Ann NY Acad Sci 1096: 184-95 (2007).
224. [224] Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 46(6): 719-30 (2009).
225. [225] Szeto HH. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8(3): E521-31 (2006).
226. [226] Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-56 (2007).
227. [227] Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 1762(2): 256-65 (2006).
228. [228] Ross MF, Prime TA, Abakumova I, James AM, Porteous CM, Smith RA, et al. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J 411(3): 633-45 (2008).
229. [229] Lee GH, Lee HY, Li B, Kim HR, Chae HJ. Bax inhibitor-1- mediated inhibition of mitochondrial Ca2+ intake regulates mitochondrial permeability transition pore opening and cell death. Sci Rep 4: 5194 (2014).
230. [230] Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med 15(10): 2025-39 (2011).
231. [231] Kraskiewicz H, FitzGerald U. InterfERing with endoplasmic reticulum stress. Trends Pharmacol Sci 33(2): 53-63 (2012).
232. [232] Gong B, Zhang LY, Pang CP, Lam DS, Yam GH. Trimethylamine N-oxide alleviates the severe aggregation and ER stress caused by G98R alphaA-crystallin. Mol Vis 15: 2829-40 (2009).
233. [233] Wu SJ, Hsieh TJ, Kuo MC, Tsai ML, Tsai KL, Chen CH, et al. Functional regulation of Alu element of human angiotensinconverting enzyme gene in neuron cells. Neurobiol Aging 34(7): 1921 e1-7 (2013).
234. [234] Ferreiro E, Oliveira CR and Pereira C. Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5- triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J Neurosci Res 76(6): 872-80 (2004).
235. [235] Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 5(206): 206ra138 (2013).
236. [236] Ghosh R, Wang L, Wang ES, Perera BG, Igbaria A, Morita S, et al. Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell 158(3): 534-48 (2014).
237. [237] Tadic V, Prell T, Lautenschlaeger J and Grosskreutz J. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front Cell Neurosci 8: 147 (2014).
238. [238] Nakajima A, Tsuji M, Inagaki M, Tamura Y, Kato M, Niiya A, et al. Neuroprotective effects of propofol on ER stress-mediated apoptosis in neuroblastoma SH-SY5Y cells. Eur J Pharmacol 725: 47-54 (2014).